All In Biotech

Drug Trial Radar · NCT07226882

A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults

A PHASE 3, PLACEBO-CONTROLLED, DOUBLE-BLINDED, RANDOMIZED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF DIFFERENT VACCINATION SCHEDULES OF 6-VALENT OSPA-BASED LYME DISEASE VACCINE, VLA15, IN HEALTHY ADULT PARTICIPANTS

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 207 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

207

Actual

Start

Nov 19, 2025

Primary completion

Jan 27, 2028

Study completion Jan 27, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 44 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of the Lyme disease vaccine (called VLA15) when given at different time points. This study is seeking participants who: * are generally healthy and between 18 and 44 years of age, * have never had a vaccine for Lyme disease before, * are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners, and * are not pregnant or breastfeeding and do not plan to become pregnant while receiving the study vaccine. All participants in this study will receive a total of 5 doses through a shot in the upper arm. Four doses will be the study vaccine (VLA15), and 1 dose will be saltwater. The study will compare the experiences of people receiving the study vaccine at different time points. This will help see if the study vaccine is safe and will help understand its effect on the body. Participants will take part in this study for about 2 years. During this time, the participants will have 11 planned visits - 8 will be at the study clinic and 3 will be done over the phone. The clinic visits may include having a health check, giving a small amount of blood (about 20 mL or 4 teaspoons), and getting the study vaccine or saltwater as a shot.

Conditions

  • Lyme Borreliosis

Interventions

  • VLA15Biological

    Participants will receive IM injection of 6-valent OspA-based Lyme disease vaccine

  • PlaceboBiological

    Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Concentration (GMC) of Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG)Time frame: At 1 month after the fourth VLA15 dose
  2. Geometric Mean Fold Rise (GMFR) of Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG) ConcentrationsTime frame: Before the first dose to 1 month after the fourth VLA15 dose
  3. Sero-Response Rate Based on Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG) Concentrations.Time frame: Before the first dose to 1 month after the fourth VLA15 dose
  4. Percentage of Participants With Local Reactions For Each GroupTime frame: Within 7 days after each vaccination
  5. Percentage of Participants With Systemic Events For Each GroupTime frame: Within 7 days after each vaccination
  6. Percentage of Participants With Adverse Events (AEs) For Each GroupTime frame: Within 1 month after each vaccination
  7. Percentage of Participants With Serious Adverse Events (SAEs) For Each GroupTime frame: From the time the participant provides informed consent up to approximately 6 months after the last vaccination
  8. Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) For Each GroupTime frame: From the time the participant provides informed consent up to approximately 6 months after the last vaccination

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • IMA Clinical Research Warren

    Warren Township, New Jersey

  • Smith Allergy and Asthma Specialists

    Cortland, New York

  • Smith Allergy & Asthma Specialists

    Horseheads, New York

  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)

    Pittsburgh, Pennsylvania

  • Northeast Clinical Trials Group

    Scranton, Pennsylvania

  • Preferred Primary Care Physicians

    Uniontown, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.